Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

Delayed Quote. Delayed  - 09/23 10:01:28 pm
81.16 USD   -0.16%
09/24 ELI LILLY AND : William Conner House
09/19DJSanofi Files Suit Against Merck
09/19 ELI LILLY AND : Everence Capital Management Inc Lowers stake in Eli ..
News SummaryMost relevantAll newsSector news 

Eli Lilly & Co. : Lilly quarterly sales, profit beats forecasts

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2012 | 02:01pm CEST

Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products.

The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because Zyprexa's decline was not as steep as had been feared, said company spokesman Mark Taylor.

The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges.

Excluding special items, Lilly earned 92 cents per share. Analysts, on average, had expected 78 cents per share, according to Thomson Reuters I/B/E/S.

The company's shares rose 2.2 percent in premarket trading.

"Lilly just reported what looks like a solid first quarter," ISI Group analyst Mark Schoenebaum said in a research note.

But Schoenebaum predicted its shares would not react in a major way since investors are more focused on the company's progress in developing solanezumab, its experimental Alzheimer's disease treatment, than on quarterly earnings.

Data from the drug's late-stage trial is expected later this year. Although the drug is considered to be a long shot, investors say it would have huge sales potential if shown to slow progress of the memory-robbing disease, and speed Lilly's return to profit growth.

Global company revenue fell 4 percent to $5.6 billion, little affected by foreign exchange rates, above Wall Street expectations of $5.36 billion.

Sales of Zyprexa, which lost U.S. patent protection in October, tumbled 56 percent to $563 million, while Cymbalta sales jumped 23 percent to $1.11 billion.

Although Cymbalta's growth helped offset declines for Zyprexa in the quarter, the depression drug's own U.S. patent will lapse in mid-2013. Its sales will then shrink dramatically, worsening Lilly's long-feared patent cliff.

Global sales of Alimta, the company's lung cancer drug, rose 5 percent to $607 million. Its Humalog insulin rose 12 percent to $590 million, while its Humulin insulin brand grew 6 percent to $308 million.

The company slightly raised its 2012 profit forecast to between $3.15 and $3.30 per share, excluding special items. In January, Lilly forecast $3.10 to $3.20 per share, far below analyst estimates, sending the drugmaker's stock down sharply.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Maureen Bavdek)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND CO
09/24 ELI LILLY AND : William Conner House
09/21 ABBVIE : Researchers say there are no benefits of testosterone treatments for me..
09/19DJSanofi Files Suit Against Merck
09/19 ELI LILLY AND : Everence Capital Management Inc Lowers stake in Eli Lilly and Co..
09/16 ELI LILLY AND : CHMP Recommends Approval of Lilly's Olaratumab, in Combination w..
09/16 ELI LILLY AND : Assigned Patent
09/15 ELI LILLY AND : An Application for the Trademark "VIEW" Has Been Filed by Eli Li..
09/15 ELI LILLY AND : Trademark Application for "SHINE" Filed by Eli Lilly
09/15 ELI LILLY AND : Crystallization plate provides clues on protein structure aboard..
09/15 ELI LILLY AND : An Application for the Trademark "SILAPUR" Has Been Filed by Eli..
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/23 Spotlight On Axovant After Lundbeck's Alzheimer's Failure
09/23 ELI LILLY JANUARY 2017 OPTIONS : An Iron Condor Idea
09/22 Biontech Deal Sees Roche Bet On mRNA
09/20 Janney sees many suitors for Clovis; shares move higher, again, in post marke..
09/19 Healthcare Top Dogs See Big Pharma Up 6-4 In September Gains
Financials ($)
Sales 2016 21 185 M
EBIT 2016 4 755 M
Net income 2016 3 316 M
Debt 2016 2 745 M
Yield 2016 2,53%
P/E ratio 2016 27,96
P/E ratio 2017 22,02
EV / Sales 2016 4,36x
EV / Sales 2017 4,15x
Capitalization 89 588 M
More Financials
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 97,5 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
John C. Lechleiter Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer
Jan M. Lundberg Executive Vice President-Science & Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO-3.68%89 588
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.32%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results